Novo Nordisk A/S Common Stock (NY:NVO)

Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision ↗

6 Stocks to Buy as European Markets Soar ↗

February 26, 2025

Via Benzinga

February 26, 2025

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug.

Via Benzinga

Topics Lawsuit

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

February 26, 2025

From Faruqi & Faruqi LLP

Why Novo Nordisk Stock Popped on Friday ↗

February 21, 2025

See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.

Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity ↗

February 19, 2025

Via Benzinga

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today ↗

February 19, 2025

Via Benzinga

Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now

February 26, 2025

Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.

Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?

February 26, 2025

The top nine American companies by market cap are all worth more than a trillion dollars.

Ranked: 10 Largest Companies In The U.S., Europe, And China ↗

February 25, 2025

Via Talk Markets

Topics Stocks / Equities

NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

February 25, 2025

From Bernstein Liebhard LLP

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cardlytics, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the Firm

February 24, 2025

From Bragar Eagel & Squire

Hims & Hers Health is on deck to report its fourth-quarter earnings late Monday. Here's what to expect.

What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle ↗

February 24, 2025

Via Investor's Business Daily

Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk ↗

February 24, 2025

President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs.

Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs ↗

February 24, 2025

Via Benzinga

Topics Government

Prediction: These Could Be the Best-Performing Value Stocks Through 2030 ↗

February 23, 2025

These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

February 23, 2025

From The Rosen Law Firm PA

Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes ↗

February 21, 2025

Via Benzinga

Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm

February 21, 2025

From Lowey Dannenberg, P.C.

The FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage ↗

February 21, 2025

Via Investor's Business Daily

Digesting Super Bowl Ads, Dunkin' & Starbucks Plans, and Some Weight Loss Drug News ↗

February 19, 2025

The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

February 19, 2025

From Faruqi & Faruqi LLP

Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages ↗

February 19, 2025

Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led to a failed Phase 3 trial.

Via Benzinga

Topics Lawsuit

Digging Into What Hershey and Eli Lilly Told Investors ↗

February 19, 2025

February 18, 2025

From Lowey Dannenberg, P.C.

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

3 Hot Stocks That Have Already Doubled in 2025 ↗

February 18, 2025

NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

February 18, 2025

From Bernstein Liebhard LLP

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes ↗

February 18, 2025

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Via Benzinga

These 3 Stocks Just Announced Major Dividend Hikes

February 18, 2025

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

February 17, 2025